Evolutec Share Discussion Threads

[frank spencer] 29/1/2007 18:18

It seems that there have been a couple/few new shareholders willing to take that risk since the bad news a few weeks ago.

Perhaps they think that buying shares in a company valued at approximately 2/3 of its cash in bank level is not such a risk.

My small holding is because of that too.

[wh0sthedaddy] 29/1/2007 17:57

cash as at 31 Dec 8.7m... might be worth a punt?

[wiganer] 29/1/2007 15:19

These tutes aren't buying a "bombed out" microcap for a laugh...

[canyfloss] 29/1/2007 15:17

we have new shareholders (they've bought 5.61%) :


RNS Number:3075Q
Evolutec Group PLC
29 January 2007



Monday 29 January 2007



Evolutec Group plc

(the "Company")



Holding in Company



The Company received notification on 25 January 2007 that Cazenove Capital
Management Ltd is interested in 1,456,000 ordinary shares of 10 pence each ("
Ordinary Shares"), representing 5.61 per cent. of the Company's issued share
capital of 25,949,996 Ordinary Shares.

[canyfloss] 29/1/2007 07:50

looks like they are in talks, and have appointed a 'specialist' broker to evaluate the value of the company.....

Evolutec Group PLC
29 January 2007

Monday 29 January 2007

Evolutec Group plc

('Evolutec' or 'Company')

Appointment of Numis Securities Limited


As previously announced on 3 January 2007, the Board of Evolutec Group plc (AIM:
EVC) is exploring all strategic options available to the Group in order to
realise value for shareholders.

The Board is pleased to announce the appointment, with immediate effect, of
Numis Securities Limited as nominated adviser and broker to assist in this
process.

Shareholders will be kept up to date with developments as appropriate and, in
any event, on announcement of the Annual Results of the Group which is due to
take place on 27 February 2007

[ant15] 25/1/2007 08:55

Fliparoo2 I got in here Market Cap 1/2 the cash in the bank and a pipeline of products that are all maturing...Pity about the announcement but well oversold.In a world when everyone is looking at acquisition opportunities within the biotech sector this is a good buy.

[pugg1ey] 24/1/2007 11:24

MM short of stock?

[mr.oz] 19/1/2007 19:52

Take out price opinions , please , too
Seems only aspect left that will give any near term prospect of gain...
(Can't believe I'm thinking of averaging down...)

[fliparoo2] 19/1/2007 19:05

landmark4

i agree. Bought in without even looking at any figures, didnt even know what the company did! With so many large houses building positions such as this & in such a short period of time it cant be long before something is going to happen. What i dont understand though is why there is so little chatter about the company, & with such obvious large scale buying of major institutions why isn't everyone (PI's) getting a piece of the pie? Any suggestions or ideas on who predator company might be and price predictions after? Would an offer be likely at this time for Evolutec?

Sorry to anyone who thinks i might be clogging the thead with poor chat, just eager to gain as much PI info as possible.
Flip

[landmark4] 17/1/2007 17:49

Almost certainly major houses are expecting a bid in the near future

Landmark

[fliparoo2] 16/1/2007 12:45

new to the stock & thread- what are people's mid term expectations? seems like a great deal of interest from major houses at start of January, adding up the holding interests (roughly, please excuse my figures) it seems like about 85% of the issued cap has been sighted by 10 big players... are they thinking long term growth or is this about to shoot? eager for views

Flip

[wiganer] 15/1/2007 10:23

Nice to see continuing strength. Does look like overhang was cleared out last week.

[frank spencer] 12/1/2007 19:07

Exactly right Pugg.

The cash gives a certain amount of protection and real value; the staff, work in progress and potential give it a value of a highly subjective nature.

[pugg1ey] 12/1/2007 10:34

remember its not just about the cash. They have some IP on molecules whilst not efficacious in the recent trials with slight modifications may be of use in other clinical indications.
I would be very surprised if a few biotech/pharma companies were not taking an interest in EVC at these levels.

[lomaximus] 12/1/2007 09:25

indeed i total agree. I'm pretty sure however that i have read somewhere that this figure had reduced i'll post it if i find it!

[madh4tter] 12/1/2007 09:11

"now dropped a large amount due to them stopping trials on rEV131."

they only stopped R&D work 2 weeks ago. they still need to pay off the payables. If you read the broker note, they do a thorough analysis of what their NET cash levels would be. The company only stated their cash levels, not their NET cash levels. Its always prudent to err on the cautious side.

[lomaximus] 12/1/2007 09:08

hmmm i need english lessons

[lomaximus] 12/1/2007 09:08

unfortunately i cant guess on exact figures but i guess it will back to the to a third of that figure like before they started trials.

[lomaximus] 12/1/2007 09:05

yes your are right i havent got to that yet however this has now dropped a large amount due to them stopping trials on rEV131.

[madh4tter] 12/1/2007 08:33

lomax

what are "Trade and other payables" ? its money that is owed to traders. Its not in the creditors sections but still money owed to other people. Its in the balance sheet, take a look again.

[lomaximus] 12/1/2007 08:25

they've been partying every night!

[lomaximus] 12/1/2007 08:23

From what i can see if you check details from the source its not showing any creditors either. Heres a link

[don muang] 12/1/2007 08:22

so how did they manage to burn about £5m in six months.... ? it can't all have been blown on the developement costs....